Abivax (NASDAQ:ABVX) Trading Down 4% – Here’s What Happened

by · The Markets Daily

Abivax SA Sponsored ADR (NASDAQ:ABVX – Get Free Report)’s share price dropped 4% during mid-day trading on Tuesday . The company traded as low as $134.26 and last traded at $134.80. Approximately 422,172 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 880,448 shares. The stock had previously closed at $140.40.

Wall Street Analyst Weigh In

ABVX has been the subject of several research reports. Guggenheim reiterated a “buy” rating and issued a $175.00 target price on shares of Abivax in a report on Thursday, December 18th. Citizens Jmp lifted their price objective on Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a report on Wednesday, October 8th. Wall Street Zen cut Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Finally, Morgan Stanley lifted their target price on Abivax from $71.00 to $101.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $128.73.

Get Our Latest Report on Abivax

Abivax Price Performance

The company has a 50 day moving average of $116.34 and a 200 day moving average of $79.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The stock has a market capitalization of $10.51 billion, a price-to-earnings ratio of -32.26 and a beta of 0.48.

Abivax (NASDAQ:ABVX – Get Free Report) last announced its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The business had revenue of ($4.92) million for the quarter. As a group, equities research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Institutional Investors Weigh In On Abivax

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL acquired a new stake in shares of Abivax during the third quarter worth about $2,792,000. FNY Investment Advisers LLC purchased a new stake in Abivax during the 3rd quarter valued at approximately $275,000. Hudson Bay Capital Management LP purchased a new stake in Abivax during the 3rd quarter valued at approximately $7,731,000. Cantor Fitzgerald L. P. acquired a new stake in Abivax during the 3rd quarter worth approximately $2,972,000. Finally, Woodline Partners LP grew its stake in shares of Abivax by 69.2% in the 3rd quarter. Woodline Partners LP now owns 311,042 shares of the company’s stock valued at $26,407,000 after purchasing an additional 127,242 shares during the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Company Profile

(Get Free Report)

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

See Also